Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/93333
標題: n-butylidenephthalide減少唐氏症誘導萬能幹細胞分化之神經細胞的類阿茲海默症病徵
n-butylidenephthalide Attenuates Alzheimer's Disease-Like Cytopathy in Down Syndrome Induced Pluripotent Stem Cell-Derived Neurons
作者: 張嘉佑
Chia-Yu Chang
關鍵字: induced pluripotent stem cells;neural stem cells;誘導萬能幹細胞;神經幹細胞;阿茲海默症
引用: 1. Tanzi, R.E. & Bertram, L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120, 545-555 (2005). 2. Turner, P.R., O'Connor, K., Tate, W.P. & Abraham, W.C. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70, 1-32 (2003). 3. Kayed, R. & Lasagna-Reeves, C.A. Molecular mechanisms of amyloid oligomers toxicity. J Alzheimers Dis 33 Suppl 1, S67-78 (2013). 4. Ballatore, C., Lee, V.M. & Trojanowski, J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8, 663-672 (2007). 5. Gotz, J., et al. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J 14, 1304-1313 (1995). 6. Honig, L.S., et al. Stroke and the risk of Alzheimer disease. Arch Neurol 60, 1707-1712 (2003). 7. Sherrington, R., et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 5, 985-988 (1996). 8. Levy-Lahad, E., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973-977 (1995). 9. Goate, A., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706 (1991). 10. Kihara, T. & Shimohama, S. Alzheimer's disease and acetylcholine receptors. Acta Neurobiol Exp (Wars) 64, 99-105 (2004). 11. Olivares, D., et al. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr Alzheimer Res 9, 746-758 (2012). 12. Dragicevic, N., et al. Green tea epigallocatechin-3-gallate (EGCG) and other flavonoids reduce Alzheimer's amyloid-induced mitochondrial dysfunction. J Alzheimers Dis 26, 507-521 (2011). 13. Mishra, S. & Palanivelu, K. The effect of curcumin (turmeric) on Alzheimer's disease: An overview. Ann Indian Acad Neurol 11, 13-19 (2008). 14. Li, F., Gong, Q., Dong, H. & Shi, J. Resveratrol, a neuroprotective supplement for Alzheimer's disease. Curr Pharm Des 18, 27-33 (2012). 15. Peng, Y., et al. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease. J Neurosci 30, 8180-8189 (2010). 16. Xiang, J., et al. L-3-n-butylphthalide improves cognitive impairment of APP/PS1 mice by BDNF/TrkB/PI3K/AKT pathway. Int J Clin Exp Med 7, 1706-1713 (2014). 17. Peng, Y., et al. L-3-n-butylphthalide regulates amyloid precursor protein processing by PKC and MAPK pathways in SK-N-SH cells over-expressing wild type human APP695. Neurosci Lett 487, 211-216 (2011). 18. Wiseman, F.K., Alford, K.A., Tybulewicz, V.L. & Fisher, E.M. Down syndrome--recent progress and future prospects. Hum Mol Genet 18, R75-83 (2009). 19. Coyle, J.T., Oster-Granite, M.L. & Gearhart, J.D. The neurobiologic consequences of Down syndrome. Brain Res Bull 16, 773-787 (1986). 20. Mann, D.M. & Esiri, M.M. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci 89, 169-179 (1989). 21. Rumble, B., et al. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med 320, 1446-1452 (1989). 22. Woods, Y.L., et al. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem J 355, 609-615 (2001). 23. Thomson, J.A., et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147 (1998). 24. Takahashi, K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007). 25. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006). 26. Schwartz, S.D., et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 385, 509-516 (2015). 27. Yahata, N., et al. Anti-Abeta drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. PLoS One 6, e25788 (2011). 28. Weick, J.P., et al. Deficits in human trisomy 21 iPSCs and neurons. Proc Natl Acad Sci U S A 110, 9962-9967 (2013). 29. Park, I.H., et al. Disease-specific induced pluripotent stem cells. Cell 134, 877-886 (2008). 30. Shi, Y., et al. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci Transl Med 4, 124ra129 (2012). 31. Lahti, A.L., et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech 5, 220-230 (2012). 32. Marchetto, M.C., et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143, 527-539 (2010). 33. Kondo, T., et al. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell 12, 487-496 (2013). 34. Israel, M.A., et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482, 216-220 (2012). 35. Chen, C., et al. Role of astroglia in Down's syndrome revealed by patient-derived human-induced pluripotent stem cells. Nat Commun 5, 4430 (2014). 36. Wen, Z., et al. Synaptic dysregulation in a human iPS cell model of mental disorders. Nature (2014). 37. Kaye, J.A. & Finkbeiner, S. Modeling Huntington's disease with induced pluripotent stem cells. Mol Cell Neurosci 56, 50-64 (2013). 38. Hibaoui, Y., et al. Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21. EMBO Mol Med 6, 259-277 (2014). 39. Lu, H.E., et al. Modeling neurogenesis impairment in Down syndrome with induced pluripotent stem cells from Trisomy 21 amniotic fluid cells. Exp Cell Res 319, 498-505 (2013). 40. Ludwig, T.E., et al. Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol 24, 185-187 (2006). 41. Chen, G., et al. Chemically defined conditions for human iPSC derivation and culture. Nat Methods 8, 424-429 (2011). 42. Watanabe, K., et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol 25, 681-686 (2007). 43. Ohgushi, M., et al. Molecular pathway and cell state responsible for dissociation-induced apoptosis in human pluripotent stem cells. Cell Stem Cell 7, 225-239 (2010). 44. Beers, J., et al. Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions. Nat Protoc 7, 2029-2040 (2012). 45. Denham, M. & Dottori, M. Signals involved in neural differentiation of human embryonic stem cells. Neurosignals 17, 234-241 (2009). 46. Chambers, S.M., et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27, 275-280 (2009). 47. Zhang, S.C., Wernig, M., Duncan, I.D., Brustle, O. & Thomson, J.A. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 19, 1129-1133 (2001). 48. Ma, L., Liu, Y. & Zhang, S.C. Directed differentiation of dopamine neurons from human pluripotent stem cells. Methods Mol Biol 767, 411-418 (2011). 49. Li, X.J., et al. Specification of motoneurons from human embryonic stem cells. Nat Biotechnol 23, 215-221 (2005). 50. Li, X.J., et al. Directed differentiation of ventral spinal progenitors and motor neurons from human embryonic stem cells by small molecules. Stem Cells 26, 886-893 (2008). 51. Chen, S.M., et al. Prerequisite Oct4 maintenance potentiates the neural induction of differentiating human embryonic stem cells and induced pluripotent stem cells. Cell Transplant (2013). 52. Maher, P., et al. ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum Mol Genet 20, 261-270 (2011). 53. Annes, J.P., Munger, J.S. & Rifkin, D.B. Making sense of latent TGFbeta activation. J Cell Sci 116, 217-224 (2003). 54. Ware, C.B., et al. Histone deacetylase inhibition elicits an evolutionarily conserved self-renewal program in embryonic stem cells. Cell Stem Cell 4, 359-369 (2009). 55. Selkoe, D.J. Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 271, 18295-18298 (1996). 56. Buerger, K., et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129, 3035-3041 (2006). 57. Fu, R.H., et al. n-butylidenephthalide protects against dopaminergic neuron degeneration and alpha-synuclein accumulation in Caenorhabditis elegans models of Parkinson's disease. PLoS One 9, e85305 (2014). 58. Xu, J., et al. L-3-n-butylphthalide improves cognitive deficits in rats with chronic cerebral ischemia. Neuropharmacology 62, 2424-2429 (2012). 59. Miyazaki, S., Takeuchi, S., Yokouchi, C. & Takada, M. Pluronic F-127 gels as a vehicle for topical administration of anticancer agents. Chem Pharm Bull (Tokyo) 32, 4205-4208 (1984). 60. Chen, G., Gulbranson, D.R., Yu, P., Hou, Z. & Thomson, J.A. Thermal stability of fibroblast growth factor protein is a determinant factor in regulating self-renewal, differentiation, and reprogramming in human pluripotent stem cells. Stem Cells 30, 623-630 (2012). 61. Furue, M.K., et al. Heparin promotes the growth of human embryonic stem cells in a defined serum-free medium. Proc Natl Acad Sci U S A 105, 13409-13414 (2008). 62. Inestrosa, N.C. & Varela-Nallar, L. Wnt signaling in the nervous system and in Alzheimer's disease. J Mol Cell Biol 6, 64-74 (2014). 63. Magdesian, M.H., et al. Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J Biol Chem 283, 9359-9368 (2008). 64. Zhang, Z., et al. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395, 698-702 (1998). 65. Rosi, M.C., et al. Increased Dickkopf-1 expression in transgenic mouse models of neurodegenerative disease. J Neurochem 112, 1539-1551 (2010). 66. Caricasole, A., et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci 24, 6021-6027 (2004). 67. Gould, T.D. & Manji, H.K. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30, 1223-1237 (2005). 68. Alvarez, A.R., et al. Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp Cell Res 297, 186-196 (2004). 69. Hooper, C., Killick, R. & Lovestone, S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104, 1433-1439 (2008). 70. Uemura, K., et al. GSK3beta activity modifies the localization and function of presenilin 1. J Biol Chem 282, 15823-15832 (2007). 71. Liu, P.Y., et al. Expression of Nur77 induced by an n-butylidenephthalide derivative promotes apoptosis and inhibits cell growth in oral squamous cell carcinoma. Invest New Drugs 30, 79-89 (2012). 72. Tsai, N.M., et al. The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo. J Neurochem 99, 1251-1262 (2006). 73. Wei, C.W., et al. n-butylidenephthalide induced apoptosis in the A549 human lung adenocarcinoma cell line by coupled down-regulation of AP-2alpha and telomerase activity. Acta Pharmacol Sin 30, 1297-1306 (2009). 74. Chiu, S.C., et al. Induction of apoptosis coupled to endoplasmic reticulum stress in human prostate cancer cells by n-butylidenephthalide. PLoS One 7, e33742 (2012). 75. Chang, C.Y., et al. N-butylidenephthalide Attenuates Alzheimer's Disease-Like Cytopathy in Down Syndrome Induced Pluripotent Stem Cell-Derived Neurons. Sci Rep 5, 8744 (2015).
摘要: 
Alzheimer's disease (AD) is a critical neuronal degenerative disease that still has no functional cure yet. Down syndrome (DS) patients with early-onset dementia share similar neurodegenerative features with Alzheimer's disease (AD). To recapitulate the AD cell model for drug screening, we first developed an economical and efficiency culture method for long term culture of human pluripotent stem cells. DS induced pluripotent stem cells (DS-iPSCs), reprogrammed from mesenchymal stem cells in amniotic fluid, were maintained in our culture system and directed toward a neuronal lineage. Neuroepithelial precursor cells with high purity and forebrain characteristics were robustly generated on day 10 (D10) of differentiation. Accumulated amyloid deposits, Tau protein hyperphosphorylation and Tau intracellular redistribution emerged rapidly in DS neurons within 45 days but not in normal embryonic stem cell-derived neurons. n-butylidenephthalide (Bdph), a major phthalide ingredient of Angelica sinensis, was emulsified by pluronic F127 to reduce its cellular toxicity and promote canonical Wnt signaling. Interestingly, we found that F127-Bdph showed significant therapeutic effects in reducing secreted Aβ40 deposits, the total Tau level and the hyperphosphorylated status of Tau in DS neurons. Taken together, our culture system can keep DS-iPSC with highly pluripotency and the DS-iPSC derived neural cells can serve as an ideal cellular model of DS and AD and have potential for high-throughput screening of candidate drugs. We also suggest that Bdph may benefit DS or AD treatment by scavenging Aβ aggregates and neurofibrillary tangles.

阿茲海默症為一種嚴重的神經退化性疾病,並且目前尚無有效的醫療方式。唐氏症患者常會罹患早發性的失智症並和阿茲海默症有類似的病理特徵。為了建立高效率的阿茲海默症細胞模型並進行藥物篩選,我們首先發展了一種較為便宜且有效率的人類萬能幹細胞無滋養層培養系統。由唐氏症胎兒羊水中取得的間質幹細胞經由重新編程後,回復成為誘導性萬能幹細胞。我們將此唐氏症誘導性萬能幹細胞進行神經分化,在分化第十天可以得到高純度的前腦神經上皮細胞。並在四十五天內我們可以發現唐氏症患者萬能幹細胞分化而來的神經元表現早期阿茲海默症的病徵,包含類澱粉蛋白的堆積、Tau 蛋白的過度磷酸化以及在神經元內表現位置改變。我們將一種當歸的主成分 n-butylidenephthalide (Bdph) 以水膠 pluronic F127 包覆以減低其細胞毒性,並且發現 F127-Bdph 有促進 Wnt 訊息傳遞路徑的活性。在經過 F127-Bdph 處理後我們發現唐氏症神經元分泌至培養液中的類澱粉蛋白以及 Tau 和磷酸化的 Tau 蛋白均有顯著的下降。結合以上結果,我們發現唐氏症萬能幹細胞為一種適當的阿茲海默症細胞模型,並對高效率的藥物篩選有良好的潛力。我們也發現一種新的小分子可能對阿茲海默症的治療有所助益。
URI: http://hdl.handle.net/11455/93333
Rights: 不同意授權瀏覽/列印電子全文服務
Appears in Collections:碩博士論文

Files in This Item:
File SizeFormat Existing users please Login
nchu-104-8098097002-1.pdf2.9 MBAdobe PDFEmbargoed until January 1, 10000    Request a copy
Show full item record
 

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.